Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China ...Middle East

- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤ 6.5% at the end of the 20-week treatment - XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China )

Also on site :

• Scott Miller Passes Away
• US has bombed nuclear sites in Iran – Trump
• 5 takeaways as US enters war with Iran, strikes nuclear sites